JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (28)
2024
2023
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437
-
The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When
Cancers, Vol. 15, Núm. 17
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, Vol. 12
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Journal of Clinical Medicine, Vol. 11, Núm. 19
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine
Human Vaccines and Immunotherapeutics, Vol. 17, Núm. 12, pp. 5129-5132
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
-
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
-
Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study
HemaSphere, Vol. 5, Núm. 3, pp. 1-8
-
The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach
Diagnostics, Vol. 11, Núm. 11
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated with Up-front Autologous Stem Cell Transplantation
Applied Immunohistochemistry and Molecular Morphology, Vol. 28, Núm. 10, pp. E94-E98
-
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
2017
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516